Drugs

, Volume 58, Issue 2, pp 203–210 | Cite as

β-Blockers in Heart Failure

The ‘New Wave’ of Clinical Trials
Leading Article

Abstract

There is now considerable clinical trial data to support the use of β-blockers in patients with congestive heart failure (CHF) due to systolic left ventricular dysfunction. A substantial database has accumulated over the last 20 years supporting the benefits of these agents on ventricular function and clinical status. In addition, morbidity and mortality benefits have been suggested, specifically with the non-selective vasodilating agent, carvedilol.

More recently, a “new wave” of clinical trials have been conducted to definitively determine the mortality benefits of β-blockers in patients with mild to moderate CHF as well as addressing other important clinical questions. These questions include whether the beneficial effects of carvedilol on survival can be reproduced by other agents in prospective, adequately powered studies; whether the benefits of carvedilol in systolic heart failure are due to its β-blocking properties alone or to a combination of the β-blocking and ancillary effects of the drug; whether β-blockers are of benefit in patients with severe New York Heart Association (NYHA) Class IIIB-IV CHF; and, whether β-blockers are of benefit (additional to ACE inhibitors) in patients with evidence of systolic ventricular dysfunction when commenced in the immediate post-myocardial infarction period.

Major studies are currently being undertaken to address the above questions. Most are still underway but 3 studies have recently reported their results: the second Cardiac Insufficiency Bisoprolol Study (CIBIS II), the Research in Left Ventricular Dysfunction Study (RESOLVD), and the Metoprolol CR/XL Randomised Intervention Trial in Heart Failure (MERIT-HF) study. These studies have demonstrated that blockade with βi-selective, non-vasodilating agents (i.e. bisoprolol and metoprolol) improve survival in patients with CHF. Comparison of relative risk reduction in these recent studies with the earlier carvedilol studies raises mechanistic questions, specifically whether non-selectivity, vasodilation and other ancillary properties of carvedilol are critical to its benefit in CHF patients. This question is currently being addressed in the Carvedilol and Metoprolol European Trial (COMET), comparing metoprolol with carvedilol.

The beneficial effects of β-blockers on mortality in patients with mild to moderate CHF have also had major implications in ongoing studies of other agents in this condition. Open-label prescribing of β-blockers is increasing in these studies and this is having an impact on event rates and thus required duration of administration of study drug. Furthermore, it would now appear unethical to deprive suitable NYHA Class II–III CHF patients of β-blockers as part of the design of such studies.

In conclusion, β-blockers have now become the most extensively studied class of agents in the treatment of CHF, with a database of over 6000 patients in placebo-controlled studies, and ongoing clinical and mechanistic studies. Despite this, further questions remain regarding the use of these agents in CHF, including their role in the extreme elderly, in patients with diabetes mellitus and in patients with renal impairment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Swedberg K. Initial experience with beta blockers in dilated cardiomyopathy. Am J Cardiol 1993; 71: 30C-8CCrossRefGoogle Scholar
  2. 2.
    Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–6PubMedCrossRefGoogle Scholar
  3. 3.
    Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; I: 1374–6CrossRefGoogle Scholar
  4. 4.
    Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471–5PubMedCrossRefGoogle Scholar
  5. 5.
    Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomised placebo-controlled trial. Circulation 1985; 72: 536–46PubMedCrossRefGoogle Scholar
  6. 6.
    Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomised study of bucindolol versus placebo. Am J Med 1990; 88: 223–9PubMedCrossRefGoogle Scholar
  7. 7.
    Krum H, Sackner-Bernstein JD, Goldsmith R, et al. Doubleblind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. Circulation 1995; 92: 1499–506PubMedCrossRefGoogle Scholar
  8. 8.
    Metra M, Nardi M, Giubbini R, et al. Effects of short-term and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678–87PubMedCrossRefGoogle Scholar
  9. 9.
    Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol 1995; 25: 1225–31PubMedCrossRefGoogle Scholar
  10. 10.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6PubMedCrossRefGoogle Scholar
  11. 11.
    CIBIS Investigators and Committees. A randomised trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994; 90: 1765–73CrossRefGoogle Scholar
  12. 12.
    Packer M, Colucci WS, Sackner-Bernstein JD, et al. Doubleblind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793–9PubMedCrossRefGoogle Scholar
  13. 13.
    CIBIS II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9–13CrossRefGoogle Scholar
  14. 14.
    White M, Rouleau JL, Perick D, et al. on behalf of the RESOLVD Investigators. Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II) (abstract). Eur Heart J 1998; 19 (Suppl.): 308CrossRefGoogle Scholar
  15. 15.
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7CrossRefGoogle Scholar
  16. 16.
    Bristow MR, Larabee P, Muller-Beckmann, et al. Effect of carvedilol on adrenergic pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992; 70: S105–S13CrossRefGoogle Scholar
  17. 17.
    Poole-Wilson PH, Remme WJ. COMET: a multicentre randomised double-blind study to compare the effect of carvedilol and metoprolol on mortality and morbidity in patients with moderate or severe congestive heart failure (NYHHA II–IV) [abstract]. Cardiovasc Drug Ther 1999 Mar; 13: 24Google Scholar
  18. 18.
    BEST Steering Committee. Design of the beta-blocker evaluation survival (BEST). Am J Cardiol 1995; 75: 1220–3CrossRefGoogle Scholar
  19. 19.
    Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol 1993; 71: 45C–53CPubMedCrossRefGoogle Scholar
  20. 20.
    Bristow MR, Hershberger RE, Port JD, et al. β-adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation 1990; 82 (Suppl. I): 12–25Google Scholar
  21. 21.
    Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Cardiac Failure 1997; 3: 173–9CrossRefGoogle Scholar
  22. 22.
    AIRE (Acute Infarction Ramipril Efficacy) study investigators. Effect of ramipril on mortaility and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  23. 23.
    Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669–77PubMedCrossRefGoogle Scholar
  24. 24.
    Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71PubMedCrossRefGoogle Scholar
  25. 25.
    Chadda K, Goldstein, CK, Byington R, et al. Effect of propranolol after acute myocardial infarction in patients with heart failure. Circulation 1986: 73: 503–10PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Clinical Pharmacology Unit, Dept. of Epidemiology & Preventive Medicine and Dept. of MedicineMonash University, Alfred HospitalPrahranAustralia

Personalised recommendations